Uriach (Spain)

Recent papers from Uriach (Spain)

1. Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional AreasCancers · 2025
2. Immersive Scientific Communication: A Multidimensional Theoretical Model for Approaching Extended Reality as a MediumPRESENCE Virtual and Augmented Reality · 2025
3. Software Sustainability: Beyond the Tower of Babel2021
4. Statistical Methods for Quality Equivalence of Topical Products. 0.5 mg/g Betamethasone Ointment as a Case-StudyPharmaceutics · 2020
5. Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: a safety, open-label, prospective studyJournal of Asthma and Allergy · 2018
6. Cardiac Safety of Rupatadine in a Single‐Ascending‐Dose and Multiple‐Ascending‐Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments—Comparison With the Previous White Caucasian Thorough QT StudyClinical Pharmacology in Drug Development · 2017
7. Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients’ Quality of Life: a Prospective, Non-interventional TrialDermatology and Therapy · 2015
8. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 yearsPediatric Allergy and Immunology · 2015
9. Platelet-activating Factor Nasal Challenge Induces Nasal Congestion and Reduces Nasal Volume in Both Healthy Volunteers and Allergic Rhinitis PatientsAmerican Journal of Rhinology and Allergy · 2013
10. Pharmacological therapies and major gastrointestinal bleeding in patients with atrial fibrillationInternational Journal of Clinical Practice · 2013
11. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double‐blind, placebo‐controlled studyPediatric Allergy and Immunology · 2013
12. Rupatadine 10 mg in the treatment of immediate mosquito‐bite allergyJournal of the European Academy of Dermatology and Venereology · 2012
13. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trialJournal of Asthma and Allergy · 2011
14. Discrimination between moderate and severe disease may be used in patients with either treated or untreated allergic rhinitisAllergy · 2010
15. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double‐blind, crossover, repeated dose, placebo‐controlled studyBritish Journal of Clinical Pharmacology · 2010
16. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelinesBritish Journal of Clinical Pharmacology · 2009
17. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mgJournal of the European Academy of Dermatology and Venereology · 2009
18. Validation of the COPD severity score for use in primary care: the NEREA studyEuropean Respiratory Journal · 2009
19. A 12‐week placebo‐controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitisAllergy · 2008
20. Versatile Three Component Coupling for the Synthesis of Pyrazolopyridines and Other Pyrido Fused SystemsHeterocycles · 2008